FDA
-
-
-
-
-
-
-
Theriva Biologics to present VCN-01 cancer trial data at AACR meeting
-
-
-
-
-
-
-
Theriva Biologics to present VCN-01 retinoblastoma trial data at APAO 2026
-
-
-
-
-
-
-
Theriva Biologics (TOVX) Announces Primary Endpoints for Efficacy and Safety Achieved in VIRAGE Phase 2b Clinical Trial of VCN-01
-
-
-
-
-
-
-
Theriva™ Biologics Reports Third Quarter 2024 Operational Highlights and Financial Results
-
-
-
-
-
-
-
Theriva Biologics (TOVX) Announces Fast Track Designation Granted by the U.S. FDA for VCN-01 for the Treatment of Metastatic Pancreatic Cancer
-
-
-
-
-
-
-
Theriva Biologics Reports Fourth Quarter and Full-Year 2022 Operational Highlights and Financial Results
-
-
328,607 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

